drugset
drugset / Trial / NCT04053972

The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

NCT04053972 ↗

Phase 3 Unknown 377 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.

Timeline

Start
2018-01-31
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenvatinib Small molecule — Oral

Indications

hepatocellular carcinoma